Double Blind Bio

1. Requirement for publicly documented enterprise compliance

• Organizations that mandate published SOC 2 Type II, ISO 27001, subprocessor lists, data residency guarantees, or detailed security architecture should consider the limited public security footprint identified and seek documentation before purchase.

2. Need to replace a CTMS

• The product is positioned as complementary to CTMS/eReg systems and does not appear to function as a full CTMS replacement.

3. Highly fragmented site data without governance

• If site capability data is frequently changing and cannot be maintained, automation may propagate inaccuracies rather than reduce workload.

4. Rigid controls on outbound sponsor communication

• If outbound sponsor messaging requires strict templating and formal approvals for every message, automated outreach workflows may increase review burden.

5. Requirement for transparent self-serve pricing

• Organizations that require clear, low-cost, monthly self-serve pricing may find a demo/quote-only procurement model to be a poor fit.

• G2: A product profile and an alternatives page are present, but publicly accessible, product-specific user review quotes were not found in the sources retrieved. G2’s categorization for the product appears broader (e.g., showing up under machine learning software), which may not reflect functional peers in clinical research.
• TrustRadius: No product page or reviews found via accessible searches.
• Gartner Peer Insights: No listing or reviews for Double Blind Bio were found in publicly accessible materials.

Public community discussions specific to Double Blind Bio are limited. Searches returned unrelated discussions about double-blind processes in science rather than vendor-specific feedback.

Some industry and partner references were identified:

• A partner directory lists Double Blind Bio as a partner and describes use of AI tools to help sites discover trials and automate feasibility.
• An industry newsletter referenced the company’s effort to structure trial information and match it to site questionnaire data.

Independent end-user reviews were not located in the accessible sources; therefore, commentary in this section relies on vendor claims, partner directory descriptions, and general industry context about feasibility workflows.

General site sentiment on feasibility (industry context): Public forum threads indicate frustration with unpaid or onerous feasibility questionnaires and inconsistent specification of feasibility requirements—a common operational challenge that vendors in this space aim to reduce.

No formal customer case studies with quantified outcomes were found in publicly accessible sources.

Note: Competing vendors in feasibility and site selection sometimes publish outcome claims (e.g., faster feasibility completion). Such vendor-published metrics should be validated for methodology, sample size, and applicability to the purchaser’s environment.

Recommendation: if the vendor provides return-on-investment (ROI) claims, purchasers should request:

• A clear definition of baseline metrics (e.g., time spent per feasibility, response rate)
• Sample size and customer segment details (therapeutic area, site type)
• Time horizon for measured outcomes
• Independent references or third-party validation where available

Double Blind Bio describes itself as a platform that uses artificial intelligence and automation to support growth and operational workflows for clinical research sites. The product is intended to help sites identify and engage with more clinical trial opportunities by:

• Discovering trial opportunities (including sources beyond ClinicalTrials.gov)
• Reducing administrative time spent on feasibility questionnaires
• Supporting sponsor outreach with templated and individualized messaging and tracking engagement
• Centralizing site intelligence (historical outreach, feasibility responses)

On public pages, Double Blind Bio emphasizes receiving inbound trial opportunities and reducing time spent on feasibility questionnaires. The site indicates that site and principal investigator profiles can be constructed by integrating with a CTMS/eReg or via document uploads. Public materials indicate trial sourcing from ClinicalTrials.gov, SEC filings, news, press releases, and articles, as well as vendor-sourced trials.

Target users (as described by the vendor and partner ecosystems):

• Clinical research sites and site networks seeking additional studies and workflow efficiencies
• Secondarily, sponsors and CROs that may benefit when sites respond faster and provide structured data

Positioning:

• The product is positioned as a front-office growth and feasibility automation layer that operates on top of existing site systems rather than as a replacement for CTMS/EDC/eReg systems.